Gene · 53345
Papers1,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sugar Rationing in the First 1000 Days After Conception and Long-Term Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Major Adverse Liver Outcomes: A Natural Experiment Study. | Clin Gastroenterol Hepatol | 2026 | 41284512 | PubTator, text mining | PubMed |
| TWAS atlas 2.0: an updated data resource for transcriptome-wide association studies. | Nucleic Acids Res | 2026 | 41251136 | PubTator, text mining | PubMed |
| Genetic Analysis of Metabolic-associated Steatosis Liver Disease in a Colombian Cohort. | J Clin Exp Hepatol | 2026 | 41210107 | PubTator, text mining | PubMed |
| Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Aliment Pharmacol Ther | 2026 | 41147688 | PubTator, text mining | PubMed |
| TM6SF2 E167K in paediatric MASLD: A genetic modifier of divergent extrahepatic outcomes. | Diabetes Obes Metab | 2026 | 41145373 | PubTator, text mining | PubMed |
| Modeling Transmembrane 6 Superfamily Member 2 p.Glu167Lys-associated Steatotic Liver Disease Using Androgen-treated Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells. | Gastro Hep Adv | 2026 | 41140757 | PubTator, text mining | PubMed |
| Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH. | Ann Hepatol | 2026 | 41135761 | PubTator, text mining | PubMed |
| Association between long-term exposure to PM10 and metabolic dysfunction-associated steatotic liver disease (MASLD) in subjects with disturbed metabolic homeostasis and genotypes at risk. | Eur J Intern Med | 2026 | 41111036 | PubTator, text mining | PubMed |
| Genetic and non-genetic drivers of histological progression and regression in MASLD. | J Hepatol | 2026 | 40998180 | PubTator, text mining | PubMed |
| Genetic variants underlying precancerous conditions of hepatocellular carcinoma. | Int J Cancer | 2026 | 40833357 | PubTator, text mining | PubMed |
| Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk. | Curr Pharm Des | 2026 | 40192053 | PubTator, text mining | PubMed |
| The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West. | Front Gastroenterol (Lausanne) | 2025 | 41822266 | PubTator, text mining | PubMed |
| Genetic risk of alcohol-related liver cirrhosis: Associations of PNPLA3, TM6SF2, and a two-variant polygenic risk score. | Biomol Biomed | 2025 | 41384813 | PubTator, text mining | PubMed |
| Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Int J Mol Sci | 2025 | 41373448 | PubTator, text mining | PubMed |
| Genetic predeterminants and recent advancements in steatotic liver disease: A roadmap toward precision hepatology. | World J Hepatol | 2025 | 41368108 | PubTator, text mining | PubMed |
| Modeling Familial MASH by iPSC-Hepatocytes. | medRxiv | 2025 | 41332850 | PubTator, text mining | PubMed |
| Investigation of the impact of gynoid fat on steatotic and advanced liver diseases-Genomic and clinical perspectives from a large-scale population cohort. | Clin Nutr | 2025 | 41314110 | PubTator, text mining | PubMed |
| Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease. | Int J Mol Sci | 2025 | 41303369 | PubTator, text mining | PubMed |
| PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children. | Front Endocrinol (Lausanne) | 2025 | 41244049 | PubTator, text mining | PubMed |
| The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different? | Front Endocrinol (Lausanne) | 2025 | 41189623 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53345/papers?page=5